News
UCLA TDG Innovation Magazine Winter 2023
UCLA TDG Innovation Magazine Winter 2023 Highlights
* UCLA TDG by the Numbers
* UCLA Ranks #1 in Scientific Publications in the LA Region
* Equatic named one of TIME Magazine's Best Inventions of 2023
* FDA Fast Track for ImmPact Bio therapeutic
* Autobahn and UCLA
and more
Autobahn Labs Announces Key Licensing Milestones in Alliances with Early University Partners
PALO ALTO, CA, USA, November 14, 2023 – Autobahn Labs, an early-stage drug discovery incubator, announced today that it had executed exclusive license agreements to foundational technologies in its collaborations with the Los Angeles and San Francisco campuses of the University of California. The objective of Autobahn’s collaborations with its academic partners is to identify academic research programs targeting important unmet medical needs and to advance their commercialization in companies it launches.
Immpact Bio receives FDA Clearance for CAR T Therapy developed at UCLA
Dual CD19 and CD20-targeting CAR T therapy offers broad immune targeting and potential to reset immune system
No neurotoxicity and only Grade 1 cytokine release syndrome in ongoing UCLA investigator-led study in lymphoma
UCLA TDG Innovation Magazine Summer 2023
Read Summer 2023 Magazine here (PDF)
In this Edition:
UCLA Life Sciences Professors among BIOS Top Women in Academic Entrepreneurship
National News Outlet tells Story of young girl with ADA-SCID
MedTech Partnering Conference 2023 Wrap Up
UCLA Innovation Fellows 2023 Cohort
UCLA Institute of Carbon Management makes great strides in 2023
Promising Data from TORL Therapeutics
Inspiring Women in Science: Yvonne Chen
To help get more girls interested in STEM, let’s spotlight inspiring women in science! A great example is Yvonne Chen, who is doing life-saving research. She is co-founder of ImmPACT Bio, which is based in Camarillo, California. The biotech company recently received positive results in its Phase 1 clinical study in relapsed/refractory B-cell Non-Hodgkin’s Lymphoma (R/R B-cell NHL).
Pfizer Chairman and CEO Dr. Albert Bourla, Keynote Speaker for LABEST 2023
Pfizer Chairman and CEO Dr. Albert Bourla to Keynote LABEST at UCLA Luskin Conference Center on May 25, 2023
TORL BioTherapeutics Launches with $158 Million Series B Financing to Advance Development of Novel Oncology Biologics
Congratulations to Dennis Slamon, M.D., Ph.D., Professor of Medicine, and Chief of the Division of Hematology/Oncology at UCLA's David Geffen School of Medicine (DGSOM) (pictured above) co-founder of TORL BioTherapeutics LLC on a successful launch!